0001743881-26-000018
SEC filingBridgeBio Pharma reported Q1 2026 financial results with $194.5 million total revenues driven by $180.6 million U.S. Attruby net product revenue and announced a $500 million stock repurchase program.
BridgeBio Pharma's Q1 2026 results demonstrated robust commercial momentum for Attruby, with U.S. net product revenue surging to $180.6 million from $36.7 million in Q1 2025, driving total revenues to $194.5 million despite a decline in license and services revenue from milestone recognition in the prior year. Royalty revenue rose to $9.5 million, reflecting growing international sales of BEYONTTRA in the EU and Japan. Operating expenses increased to $300.5 million, primarily from $57.5 million higher SG&A for Attruby commercialization and pre-commercial activities, plus elevated R&D and cost of revenues tied to product sales. This resulted in an operating loss of $106.0 million and net loss of $164.0 million or $0.84 per share, a slight improvement from $0.88 per share last year. Cash position strengthened to $940.2 million from $587.5 million at year-end 2025, supporting pipeline advancement. The $500 million share repurchase program signals management's view that shares trade at a discount to intrinsic value, offering attractive returns amid a fully financed position. Pipeline progress includes BBP-418 NDA submission for LGMD2I/R9, with potential priority review and U.S. launch in late 2026/early 2027; encaleret NDA planned for 1H 2026 post-positive Phase 3; and infigratinib NDA in Q3 2026. Attruby's real-world data and Brazil approval further differentiate it from tafamidis, with upcoming presentations at ESC Heart Failure 2026 reinforcing survival benefits.